Adinazolam (Deracyn®) is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was first developed to enhance the antidepressant effects of alprazolam. It has never been approved by...
- Mechanism
- Curator reviewed
Adinazolam binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
- Primary indication
- For the treatment of anxiety and status epilepticus.Curator reviewed
- Formula / weight
- C19H18ClN5 · 351.833 g/mol (avg)
- Code names
- U-41,123
Resolves to
GJSLOMWRLALDCT-UHFFFAOYSA-NSMILESCN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12What you can answer from here — as of September 23, 2026
Which drugs share a target with Adinazolam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account